Active smoking and bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD): a hazardous combination in causing cardiovascular disease?

Active smoking and bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD): a hazardous combination in causing cardiovascular disease? - Interaction in COPD Experiment (ICE)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33894

Enrollment

Registered

2009-05-20

Start date

2009-09-20

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovascular disease emphysema heart disease. chronic obstructive pulmonary disease

Interventions

Patients recieve whether a bronchodilator or a placebo twice, preceded and followed by repeatedly inhaling cigarette smoke during two hours as by a strict time schedule.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: active cigarette smoker COPD gold klasse II-III

Exclusion criteria

Exclusion criteria: not mastering the Dutch language not capable of following technical instructions not willing to withheld from smoking and bronchodilation for a certain time before the study recent exacerbation within the last 2 weeks before the experiment asthmatic component

Design outcomes

Primary

Measure	Time frame
1. The fraction of cigarette smoke particles and constituents retained in the lungs related to the (changed) lungfunction. 2. The concentration of certain biomarkers associated with cardiovascular dysfunction and risk, related to the (changed) lungfunction.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)